Replies to post #42901 on Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

The other interesting comment from NRX SEC filing June 2021 was he listed that there is possibility that their drug zyesami might be ruled as an infringement on the valid patent rights of another party. Why would you document that on the SEC filing if your are claiming there is no patent?

~ CA_Newby, Y@h00 RLFTF finance conversations

Reply:

I think JJ was hoping he could strong arm RLF again into better terms. They caved to the initial pressure and added his revenue split. He probably thought that he could get more now so close to the EUA. These comments were in June soon after EUA filed. He already had a game plan, began paying his family right after the CA and he received $10.6 million for study plus $1 million for formulation study no questions asked. Since the game to send bloated receipts beyond 30% overage failed he is desperately trying to salvage, coverup or distracted from the real issue.

~CA_Newby, Y@h00 RLFTF finance conversations